Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs Sana Biotechnology Inc (SANA) Price & Performance

Caterpillar IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs Sana Biotechnology Inc — how do they compare? Caterpillar Inc trades at $893.28 (market cap $429.89B), while Sana Biotechnology Inc trades at $3.48 (market cap $994.89M). The key difference: Caterpillar Inc is far larger — about 432.1× Sana Biotechnology Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

CATSANA
Market Cap
$429.89B$994.89M
Sector
IndustrialsHealth
52-Week High
$1.06K$5.92
52-Week Low
$404.64$2.68
Enterprise Value
$468.88B$969.08M
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $931.47, down 2.2% on the day, but has gained 51% year-to-date, driven by strong earnings beats and AI-related infrastructure demand. The stock shows a bullish moving average signal but neutral overall technicals, with support near $922. Revenue reached $67.59 billion in 2025, with a net income margin of 13.33%, though valuation multiples like a P/E of 46.48 appear elevated. Recent news highlights its role in the AI data center boom, with the Power & Energy segment seeing significant backlog growth.

The outlook remains positive given analyst consensus and AI-driven tailwinds, but high valuation and exposure to economic cycles pose risks. With 55% of analysts rating it a Buy and a consensus price target of $1,030, upside potential exists, though investors should weigh margin pressures and debt levels against growth catalysts from data center and infrastructure spending.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.

The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA